{"version":"1.0","provider_name":"Asimas","provider_url":"https:\/\/www.asimas.it\/new_asimas","title":"AYVAKYT (AVAPRITINIB) approvato dalla Commissione Europea - Asimas","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"jeuyYONSoS\"><a href=\"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/\">AYVAKYT (AVAPRITINIB) approvato dalla Commissione Europea<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/embed\/#?secret=jeuyYONSoS\" width=\"600\" height=\"338\" title=\"&#8220;AYVAKYT (AVAPRITINIB) approvato dalla Commissione Europea&#8221; &#8212; Asimas\" data-secret=\"jeuyYONSoS\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.asimas.it\/new_asimas\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"&nbsp; Ciao mondo Asimas! &nbsp; La Blueprint Medicines Corporation ha annunciato pochi giorni fa che la Commissione Europea ha approvato il farmaco AYVAKYT (AVAPRITINIB) per il trattamento di pazienti adulti affetti da mastocitosi sistemica indolente con sintomi da moderati a gravi non adeguatamente controllati dal trattamento sintomatico. Nell&#8217;Unione Europea i pazienti affetti da mastocitosi sistemica [&hellip;]","thumbnail_url":"https:\/\/static.xx.fbcdn.net\/images\/emoji.php\/v9\/t1e\/2\/16\/1f60a.png"}